Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease
Journal of the Association of Physicians of India · 2025
DOI: 10.59556/japi.73.1250 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the Association of Physicians of India, 2025. Verfasst von Vijay Panikar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Consultant, Department of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India, Corresponding Author. Hauptthemen laut MEDLINE: Pioglitazone, Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Among liver disorders, nonalcoholic fatty liver disease (NAFLD) is the most common and is associated with metabolic syndromes, particularly type 2 diabetes mellitus (T2DM). This study aimed to assess the effectiveness of pioglitazone in the management of T2DM with NAFLD.
Methods
This retrospective, single-center, observational study was carried out at Dr Panikar’s Speciality Care Centre from 1st September 2022 to 1st February 2024. The data were collected from the medical records of diabetic patients with NAFLD who received pioglitazone. Patients aged between 18 and 80 years who had diabetes along with NAFLD were included in the study.
Results
A total of 3,350 patients were enrolled in this study, of whom 2,074 were male, with a mean age of 48.6 years. The mean estimated A1C (eA1C) showed a significant reduction at 6 months compared to baseline (6.87 vs 7.6%; mean difference (95% CI): 0.50% (0.39, 0.61); p < 0.001). At baseline, the mean controlled attenuation parameter (CAP) was significantly higher than at 6 months (p = 0.032). Similarly, the mean cholesterol level was significantly higher at baseline compared to 6 months (p = 0.020). A 25.7% decrease in grade 3 fatty liver was noted over the 6-month period from baseline. In terms of the decrease in fibrosis severity, a 37.5% reduction in F2, a 25.8% reduction in F1, and a 17.6% reduction in F4 were observed from baseline to 6 months.
Conclusion
In T2DM patients with NAFLD, pioglitazone improves glycemic control and reduces both fatty liver grades and fibrosis stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Consultant, Department of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India, Corresponding Author.
- Resident, Department of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India.
- Associate Professor, Department of Medicine, BKL Walawalkar Rural Medical College, Chiplun, Maharashtra, India.
- Consultant, Department of Endocrinology, Lilavati Hospital, Mumbai, Maharashtra, India, Orcid: https://orcid.org/0000-0003-2741-5022.
- Consultant, Dr Panikar Diabetes Care, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
- Consultant Physician and Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra, India, Orcid: https://orcid.org/0000-0003-4024-0095.
Zitieren
APA
Panikar, V., Gupta, A., Nasikkar, N., Joshi, S., Walwalkar, S., Sachdev, I., Tiwaskar, M., Panikar, K., Mahajan, A., Deogaonkar, N., Vadgama, J., Tuteja, H., Lalwani, D., Singh, S., & Kader, P. (2025). Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease. Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.73.1250
Vancouver
Panikar V, Gupta A, Nasikkar N, Joshi S, Walwalkar S, Sachdev I, et al. Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease. Journal of the Association of Physicians of India. 2025. doi:10.59556/japi.73.1250
BibTeX
@article{Panikar2025,
author = {Panikar, Vijay and Gupta, Apoorva and Nasikkar, Nikhil and Joshi, Shashank and Walwalkar, Sanhita and Sachdev, Ishita and Tiwaskar, Mangesh and Panikar, Krish and Mahajan, Aditi and Deogaonkar, Narayan and Vadgama, Jimit and Tuteja, Harshpreet and Lalwani, Divya and Singh, Samiksha and Kader, Parveen},
title = {Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease},
journal = {Journal of the Association of Physicians of India},
year = {2025},
doi = {10.59556/japi.73.1250}
}
EUVIMED